Akron Biotech Attends the MIT Center for Biomedical Innovation’s 2018 BioMAN Summit in Cambridge

The MIT Center for Biomedical Innovation (CBI) leads the Biomanufacturing (BioMAN) program, an initiative that joins leaders from industry, academia, and government to address collective challenges in biologics manufacturing by creating a pre-competitive environment in which stakeholders can share best practices and engage in collaborative work. Akron Biotech attended this year’s summit in Cambridge, MA

SCB Perspectives: ISO Publishes Three-Part Documentary Standard on Ancillary Materials for Cell Manufacturing Processes

This blog post was originally shared at standardscoordinatingbody.org. Claudia Zylberberg, SCB Board Member, Akron Biotech December 17, 2018 I’m pleased to announce that one of the first standards advancement projects SCB was involved in, Ancillary Materials Used in Cellular Therapy Production, has culminated in the publication of a three-part documentary ISO standard (ISO/TS 20399): Part

Join Akron at SITC 2018

This week, from Wednesday November 7 through Sunday November 11, Akron Biotech representatives will be attending the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. SITC 2018 is the leading destination for scientific exchange, education and networking in the cancer immunotherapy field. As an innovative

Upcoming Events – September 2018

As a scorching summer draws to a close and conference season begins, Akron will be participating at many upcoming events to further advocate for the use of higher quality ancillary materials in regenerative medicine processes.  Our focus of providing affordable cGMP reagents throughout the development stages for these unique therapeutics serves to better ensure reproducibility

Akron co-sponsors the 11th annual Business of Regenerative Medicine Symposium at the University of Pennsylvania

The 11th annual Business of Regenerative Medicine: Innovation, Clinical Translation, and Entrepreneurship Symposium took place on July 17th-18th. The event was hosted by the Center for Cellular Immunotherapies and the Institute for Regenerative Medicine at the University of Pennsylvania in partnership with Case Western Reserve University, the Harvard Stem Cell Institute, the Parker H. Petit

Akron remains committed to our regenerative medicine partners, both domestic and international

The recent EMA recommendation for approval of Kymriah and Yescarta serves as yet another sign of the commercial arrival of cell therapies and their growing global appeal. As these novel therapeutics expand beyond US boundaries, Akron has taken the following steps to help our clients better understand the regional regulatory differences, innovations and tools available

Akron Biotech and U.S.-based industry leaders meet with the Argentine regulatory authority (ANMAT) to discuss regulatory developments in regenerative medicine

Last week, the Akron team joined more than 1,600 participants from 50+ countries at the annual meeting of the International Society for Cell and Gene Therapy (ISCT) in Montreal. Chaired by David DiGiusto, PhD (Stanford School of Medicine), Sarah Nikiforow, MD, PhD (Dana Farber Cancer Institute), and Denis-Claude Roy, MD, FRCPC (Hôpital Maisonneuve-Rosemont), the meeting

Join Akron at ISCT 2018

Riding the commercial approvals of two CAR T immunotherapies last year, the energized regenerative medicine community will be coming together in Montreal for the Annual ISCT Global Meeting and Exhibition from Wednesday May 2nd through Saturday May 5th. Don’t miss Dr. Claudia Zylberberg, CEO of Akron Biotech, during the Quality & Operations Track speaking about

Innate Killer Summit 2018 presents cutting-edge innovations and the latest clinical data for NK cell therapies

Akron Biotech was proud to be a sponsor of this year’s Innate Killer Summit held in San Diego, California. The Innate Killer Summit is the leading, dedicated end-to-end meeting serving as a catalyst to ensure successful clinical and commercial translation of NK cell immunotherapies. The most current and advanced clinical data was presented as well